Induction of apoptosis via Fas system and enhancement of the induction in bile duct carcinoma cells
Induction of apoptosis via Fas system and enhancement of the induction in bile duct carcinoma cells
批准号:
11671276
负责人:
MARUNO Kaname
金额:
$2.05万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Results1. Fas expression in bile duct carcinoma (BDC) cells, analyzed by flow cytometry : Fas was expressed at 21.7% in HuCCT1 cells and at 30.9% in HuH28 cells, respectively.2. Viability of BDC cells treated with anti-Fas monoclonal antibody (mAb), CH-11 which induces apoptosis : CH-11 dose-dependently reduced HuCCT1 and HuH28 cell counts at the concentration range from 0.01 to 1.0 μg/ml by up to 16.4% and 71.7% on day 3, respectively.3. DNA fragmentation in BDC cells treated with CH-11 or IFN-γ : In HuCCT1 and HuH28 cells treated with CH-11 or IFN-γ, the peak corresponding to that of positive control cells was observed.4. Morphological changes of BDC cells treated with CH-11 or IFN-γ : The shrinkage of cells, chromatin condensation and nuclear fragmentation were observed as morphological changes characteristic of apoptosis.5. Inhibitory effect of anti-Fas mAb 4B4, which does not induce apoptosis, on the induction of apotosis by CH-11 : 4B4 inhibited the reduction of cell counts by 41 … More .7% in HuH28 cells.6. Enhancement of Fas expression in BDC cells treated with IFN-γ : In HuCCT1 cells, the Fas expression was enhanced by 17.6%. In HuH28 cells, however, IFN-γ did not affect the Fas expression.7. Effect of pretreatment with IFN-γ on the viability of BDC cells treated with CH-11 : Pretreatment with IFN-γ increased the reduction of HuCCT1 and HuH28 cell counts by 41.2% and 8.2% on day 3, respectively.8. Effect of pretreatment with IL-2 on the viability of BDC cells treated with CH-11 : In HuCCT1 cells, IL-2 alone did not affect the cell number on day 3. Pretreatment with IL-2 also did not affect the reduction of cell counts. In HuH28 cells, IL-2 alone reduced the cell counts by 11.2% on day 3. Pretreatment with IL-2 also did not affect the reduction of cell counts.9.Viability of BDC cells treated with INF-γ : INF-γ dose-dependently reduced HuCCT1 and HuH28 cell counts at the concentration range from 0.1 to 100 U/ml by up to 45.1% and 87.8% on day 3, respectively.10. Caspases in BDC cells treated with CH-11 or INF-γ. Any caspase was not detected in HuCCT1 cells. Caspase-3 was detedeted in HuH28 cells treated with CH-11 for 8 hr.Conclusions1. Fas was expressed in human BDC cells.2. Apoptosis was induced by anti-Fas mAb and IFN-γ in human BDC cells.3. Induction of apoptosis by CH-11 was inhibited by 4B4 in human BDC cells.4. The expression of Fas and the induction of apoptosis was enhanced by IFN-γ in human BDC cells.5. Caspase-3 was activated in BDC cells treated with anti-Fas mAb. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于WTAP/METTL3-KRT8-FAS轴探讨卵巢子宫内膜样癌预后及化疗敏感性的临床研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:章杰捷
-
依托单位:
基于Fas/Fas-L 信号通路探讨肾小管上皮细胞外泌体对椎间
盘退变的影响及补肾活血汤干预机制
-
批准号:2024JJ9464
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:罗继
-
依托单位:
STAB1调控Fas/FasL介导牦牛胎盘滋养层细胞凋亡及胎盘炎症性流产的作用与机制研究
-
批准号:32360836
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:张全伟
-
依托单位:
土家药血筒中血筒素抗RA药效及Fas/caspase-8/-3通路介导滑膜细胞凋亡机制研究
-
批准号:2023JJ40490
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:余黄合
-
依托单位:
斑点热立克次体通过GBP1上调FAS/Caspase-8促进血管内皮细胞凋亡的分子机制研究
-
批准号:82302568
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:何茂章
-
依托单位:
大肠杆菌促进Fas/FasL介导的胆管上皮细胞凋亡在原发性胆汁性胆管炎中的机制研究
-
批准号:82300608
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:李燕妮
-
依托单位:
Nynrin通过转录调控促进Fas表达进而维持AML白血病干细胞存活的分子机制研究
-
批准号:CSTB2023NSCQ-MSX0293
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:周成芳
-
依托单位:
蒙药清肝九味散通过Fas/FasL途径调控HSC凋亡抗肝纤维化的作用机制研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:戈宏焱
-
依托单位:
基于肠—肝轴研究沙棘甾醇调控SREBP-1c/FAS信号通路治疗非酒精性脂肪性肝病的作用机制
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:31万元
-
批准年份:2022
-
负责人:张得钧
-
依托单位:
二至猫苓汤通过METTL3/14甲基化酶介导卵巢癌KRT8 m6A甲基化调控FAS凋亡信号通路研究
-
批准号:82274266
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:于爱军
-
依托单位: